Literature DB >> 35476671

Optineurin promotes myogenesis during muscle regeneration in mice by autophagic degradation of GSK3β.

Xiao Chen Shi1, Bo Xia1, Jian Feng Zhang1, Rui Xin Zhang1, Dan Yang Zhang1, Huan Liu1, Bao Cai Xie1, Yong Liang Wang1, Jiang Wei Wu1.   

Abstract

Skeletal muscle regeneration is essential for maintaining muscle function in injury and muscular disease. Myogenesis plays key roles in forming new myofibers during the process. Here, through bioinformatic screen for the potential regulators of myogenesis from 5 independent microarray datasets, we identify an overlapping differentially expressed gene (DEG) optineurin (OPTN). Optn knockdown (KD) delays muscle regeneration in mice and impairs C2C12 myoblast differentiation without affecting their proliferation. Conversely, Optn overexpression (OE) promotes myoblast differentiation. Mechanistically, OPTN increases nuclear levels of β-catenin and enhances the T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription activity, suggesting activation of Wnt signaling pathway. The activation is accompanied by decreased protein levels of glycogen synthase kinase 3β (GSK3β), a negative regulator of the pathway. We further show that OPTN physically interacts with and targets GSK3β for autophagic degradation. Pharmacological inhibition of GSK3β rescues the impaired myogenesis induced by Optn KD during muscle regeneration and myoblast differentiation, corroborating that GSK3β is the downstream effector of OPTN-mediated myogenesis. Together, our study delineates the novel role of OPTN as a potential regulator of myogenesis and may open innovative therapeutic perspectives for muscle regeneration.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35476671      PMCID: PMC9084533          DOI: 10.1371/journal.pbio.3001619

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   9.593


Introduction

Skeletal muscle, the most abundant tissue in our bodies, plays key roles in posture, mobility, and energy metabolism [1]. In muscle injury and muscular disease, the regeneration capacity of skeletal muscle is essential for restoration of these functions [2,3]. In response to muscle injury, satellite cells (SCs) will be activated to start myogenic differentiation, accompanied with up-regulated expression of myogenin (MYOG) and muscle-specific regulatory factor 4 [4,5]. The differentiation program is then completed with the activation of muscle specific proteins such as MYHC in myoblasts that subsequently fuse to regenerate myofibers to repair damaged muscle [2]. Therefore, myoblast differentiation-mediated myogenesis plays essential roles in muscle regeneration. Nonetheless, the underlying mechanisms of myogenesis during muscle regeneration remain largely unknown. To explore the potential regulators of myogenesis, we performed bioinformatics screen from 5 myogenesis-related microarray datasets and identified optineurin (Optn) as one of the 5 overlapping genes, up-regulated during myoblast differentiation and muscle regeneration, while down-regulated in Duchenne muscular dystrophy (DMD) patients and mdx mice. The human OPTN is a 74-kDa scaffold protein comprised of 577 amino acids, and the mouse Optn gene encodes for a 584-amino acid protein (67 kDa), which is 78% identical to human OPTN [6]. OPTN is expressed in most tissues, including muscle, liver, and brain [7-9], and plays important roles in many cellular functions [6]. It has been identified as a selective autophagy receptor involved in the various stages of the autophagic process such as cargo recognition, autophagosome formation, and autophagic degradation [10]. OPTN mutations were shown in several familial diseases and often occur in its autophagy-associated ubiquitin-binding domain (UBAN) [11], such as OPTN E478G in amyotrophic lateral sclerosis (ALS) [7] and OPTN R545Q in normal-tension glaucoma [12]. OPTN is highly expressed in the skeletal muscle [13], yet little is known about the role of OPTN in myogenesis and whether its function in skeletal muscle is related to autophagy. The canonical Wnt signaling pathway plays critical roles in facilitating the differentiation of SCs during skeletal muscle regeneration [14-16]. Wnt ligands bind to frizzled receptors and members of the low-density lipoprotein receptor related protein family, activating the nuclear translocation of β-catenin and the formation of a complex with the T-cell factor/lymphoid enhancer factor (TCF/LEF) [17]. It enhances transcriptional activity of myogenic factors such as myogenic factor 5 (Myf5) [18], myoblast determination protein (Myod) [19], fermitin family homolog 2 (Fermt2) [20], and Myog [21] during muscle regeneration. Wnts promote β-catenin nuclear translocation through inhibition of glycogen synthase kinase 3β (GSK3β), an important component of β-catenin destruction complex [22]. Genetic deletion or pharmacological inhibition of GSK3β leads to enhanced differentiation of C2C12 cells and muscle regeneration [23,24], indicating that GSK3β is essential for Wnt signaling pathway–mediated myoblast differentiation. Nevertheless, mechanism of Wnt-mediated suppression of GSK3β remains incompletely resolved and in dispute. A GSK3β-mediated crosstalk of autophagy and canonical Wnt signaling pathway has been shown during embryogenesis [25-27]. Whether the autophagy receptor OPTN is involved in the GSK3β-mediated canonical Wnt signaling pathway during muscle regeneration is completely unknown. In this study, we show that OPTN is required for myoblast differentiation-mediated myogenesis during muscle regeneration in mice. OPTN promotes Wnt signaling pathway mediated myogenesis through direct physical interaction and autophagic degradation of GSK3β. Our findings reveal a new insight into mechanism underlying myogenesis during muscle regeneration and provide a potential target for muscle regeneration.

Results

Bioinformatic screen reveals OPTN as a potential regulator for myogenesis

To search for potential regulators of myogenesis, we compiled and intercrossed differentially expressed genes (DEGs) in 5 independent microarray datasets related to myogenesis from the Gene Expression Omnibus (GEO) database: (i) DEGs during C2C12 cell differentiation (GSE11415); (ii) DEGs during cardiotoxin (CTX)-induced muscle regeneration in mice (GSE45577); (iii) DEGs in skeletal muscle of DMD patients (GSE1004); (iv) DEGs in gastrocnemius muscle of murine X-linked muscular dystrophy (mdx) mice (GSE16438); and (v) DEGs in vastus lateralis between young (21 to 31 years old) and old (62 to 77 years old) men (GSE80). Comprehensive analysis of the datasets yielded 5 overlapping genes ankyrin repeat domain 1 (Ankrd1), galectin 3 (Lgals3), doublecortin like kinase 1 (Dclk1), myosin heavy chain 8 (Myh8), and Optn (Fig 1A). Among them, Ankrd1, Lgals3, Dclk1, and Myh8 have been well characterized in the regulation of myogenesis [28-32]. The roles of OPTN, a selective autophagy receptor [33], remain unclear in myogenesis.
Fig 1

OPTN is essential for myogenesis during skeletal muscle regeneration in response to muscle injury.

(A) Venn diagram showing 5 overlapping DEGs among 5 independent microarray datasets related to myogenesis or muscle atrophy. (B) Representative immunoblotting analysis of eMYHC and OPTN in TA of WT mice at 0, 3, 5, and 14 days postinjury (n = 3 mice in each group). (C) Representative immunofluorescence analysis of OPTN subcellular distribution in TA muscle at CTX untreated or 5 days postinjury. The OPTN, the sarcolemma, and the nucleus were stained with anti-OPTN antibody (red), WGA (green), and DAPI (blue), respectively. Scale bars: 20 um. (D) Representative HE staining of TA at 0, 3, 5, and 14 days postinjury in scramble shRNA or shOptn mice. The yellow arrowheads indicate inflammatory cells infiltration. Scale bar: 50 μm. (E) Representative immunofluorescence staining of eMYHC+ fibers in scramble shRNA or shOptn TA muscle at 5 days postinjury. Scale bar: 20 μm. (F) Distribution of eMYHC+ myofiber CSAs in scramble shRNA or shOptn TA muscle at 5 days postinjury (n = 5 mice in each group). (G) Average CSA of regenerating eMYHC+ myofibers in scramble shRNA or shOptn TA muscle at 5 days postinjury (n = 5 mice in each group). (H–J) Representative immunoblotting analysis (H) and quantification (I, J) of myogenic markers (eMYHC and MYOG) in scramble shRNA or shOptn TA muscle (n = 3 mice in each group) at 5 days postinjury. M, marker. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; Ankrd1, ankyrin repeat domain 1; CTX, cardiotoxin; CSA, cross-sectional fiber area; Dclk1, doublecortin like kinase 1; DEG, differentially expressed gene; DMD, Duchenne muscular dystrophy; eMYHC, embryonic myosin heavy chain; HE, hematoxylin–eosin; Lgals3, galectin 3; mdx, murine X-linked muscular dystrophy; Myh8, myosin heavy chain 8; MYOG, myogenin; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior; WGA, wheat germ agglutinin; WT, wild-type.

OPTN is essential for myogenesis during skeletal muscle regeneration in response to muscle injury.

(A) Venn diagram showing 5 overlapping DEGs among 5 independent microarray datasets related to myogenesis or muscle atrophy. (B) Representative immunoblotting analysis of eMYHC and OPTN in TA of WT mice at 0, 3, 5, and 14 days postinjury (n = 3 mice in each group). (C) Representative immunofluorescence analysis of OPTN subcellular distribution in TA muscle at CTX untreated or 5 days postinjury. The OPTN, the sarcolemma, and the nucleus were stained with anti-OPTN antibody (red), WGA (green), and DAPI (blue), respectively. Scale bars: 20 um. (D) Representative HE staining of TA at 0, 3, 5, and 14 days postinjury in scramble shRNA or shOptn mice. The yellow arrowheads indicate inflammatory cells infiltration. Scale bar: 50 μm. (E) Representative immunofluorescence staining of eMYHC+ fibers in scramble shRNA or shOptn TA muscle at 5 days postinjury. Scale bar: 20 μm. (F) Distribution of eMYHC+ myofiber CSAs in scramble shRNA or shOptn TA muscle at 5 days postinjury (n = 5 mice in each group). (G) Average CSA of regenerating eMYHC+ myofibers in scramble shRNA or shOptn TA muscle at 5 days postinjury (n = 5 mice in each group). (H–J) Representative immunoblotting analysis (H) and quantification (I, J) of myogenic markers (eMYHC and MYOG) in scramble shRNA or shOptn TA muscle (n = 3 mice in each group) at 5 days postinjury. M, marker. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; Ankrd1, ankyrin repeat domain 1; CTX, cardiotoxin; CSA, cross-sectional fiber area; Dclk1, doublecortin like kinase 1; DEG, differentially expressed gene; DMD, Duchenne muscular dystrophy; eMYHC, embryonic myosin heavy chain; HE, hematoxylin–eosin; Lgals3, galectin 3; mdx, murine X-linked muscular dystrophy; Myh8, myosin heavy chain 8; MYOG, myogenin; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior; WGA, wheat germ agglutinin; WT, wild-type.

OPTN is essential for myogenesis during skeletal muscle regeneration

To investigate the role of OPTN in myogenesis during muscle regeneration, we analyzed OPTN expression during CTX-induced muscle injury in mice. Compared with uninjured muscle (day 0), OPTN expression was significantly up-regulated during the initial phase of muscle regeneration (day 5), and then decreased at day 14, similar to the expression profile of the newly regenerated myofiber marker embryonic myosin heavy chain (eMYHC) (Fig 1B, S1A and S1B Fig). In line with this, the immunofluorescence analysis also showed increased OPTN in the cytoplasm of newly regenerated myofibers at 5 days postinjury (Fig 1C, S2 Fig). These results indicate a potential role of OPTN in muscle regeneration. We further generated a recombinant adeno-associated viral vector (AAV) with a short hairpin RNA (shRNA) targeting Optn (AAV-shOptn) (S3A and S3B Fig), which achieved 72% reduction in mRNA levels and 76% reduction in protein levels compared with scramble shRNA in tibialis anterior (TA) muscle (S3C and S3D Fig). The TA muscle receiving AAV scramble shRNA or shOptn was subjected to a single CTX injury and then allowed to recover for 3 to 14 days before analysis of the regenerated tissue. In scramble shRNA muscle, SCs descendants fused to form new myofibers characterized by centrally localized nucleus during the acute phase of regeneration (3 to 5 days after injury) (Fig 1D). The eMYHC+ fibers were abundant at day 5 postinjury (Fig 1E). In contrast, AAV-shOptn muscle was composed of degenerating myofibers, fibrotic tissues, and inflammatory cells at this phase (Fig 1D). The eMYHC+ regenerating fibers in AAV-shOptn muscle were less and smaller at day 5 postinjury compared with scramble shRNA muscle (Fig 1E–1G). In line with this, the protein levels of eMYHC and MYOG were significantly reduced in AAV-shOptn muscle at day 5 postinjury (Fig 1H–1J). Fourteen days after injury, muscle damage and inflammatory cells in scramble shRNA muscle were largely cleared, and the regenerated myofibers continued to grow and mature, as they became homogenous in size (Fig 1D), whereas small regenerated fibers and a few inflammatory cells were still shown in shOptn TA muscle (Fig 1D). These data show that Optn knockdown (KD) delayed skeletal muscle regeneration in adult mice, indicating an essential role of OPTN in myogenesis during muscle regeneration.

OPTN promotes myoblast differentiation-mediated myogenesis

In response to muscle injury, muscle SCs undergo massive proliferation and differentiation to form new myotubes that replace the damaged myofibers [34]. To explore the role of OPTN in myogenesis during muscle regeneration, we first detected the effect of OPTN on muscle SCs proliferation and found similar paired box 7+ (Pax7) 5-ethynyl-20-deoxyuridine+ (EdU) SCs frequency in shOptn and scramble shRNA TA muscle at day 3 postinjury (S4A–S4D Fig). In addition, Optn KD in C2C12 cells had no effect on numbers of EdU+ cells and the expression of cell proliferation-associated genes (S4E–S4G Fig). These results suggest that OPTN does not affect SCs proliferation during muscle regeneration. We next investigated whether OPTN-mediated myogenesis is achieved by regulation of myoblast differentiation. OPTN expression was increased during C2C12 myoblast differentiation with MYHC colocalization, similar to the expression patterns of MYOG (Fig 2A and 2B, S5A and S5B Fig). Optn KD in C2C12 cells reduced cell fusion and multinuclear myotube formation events (Fig 2C–2E), along with decreased levels of MYOG and MYHC (Fig 2F–2H, S6A and S6B Fig). In contrast, Optn overexpression (OE) (plasmid HA-Optn) in C2C12 cells dramatically enhanced myoblast differentiation (Fig 2I–2K), accompanied with increased levels of MYOG and MYHC (Fig 2L–2N, S6C and S6D Fig). Together, these findings indicate that OPTN promotes myoblast differentiation-mediated myogenesis.
Fig 2

OPTN promotes myoblast differentiation mediated myogenesis.

(A) Representative immunoblotting analysis of OPTN and MYOG in C2C12 cells during differentiation at the indicated time points (0, 2, 4, 6, and 8 days) (n = 3 in each group). (B) Representative immunofluorescence analysis of OPTN subcellular distribution in myotubes. The OPTN and MYHC were stained with anti-OPTN antibody and anti-MYHC antibody in C2C12 cells at 4 days postdifferentiation. Scale bars: 10 um. (C) Representative immunofluorescence staining of MYHC in control (si-control) or Optn KD (si-Optn) C2C12 cells at 4 days postdifferentiation. si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (D, E) Quantification of the nucleus distribution per myotube and fusion index (a MYHC+ cell with at least 3 nucleus) in control (si-control) or Optn KD (si-Optn) C2C12 cells at 4 days postdifferentiation (n = 4 in each group). (F–H) Representative immunoblotting analysis (F) and quantification (G, H) of MYHC and MYOG in control (si-control) or Optn KD (si-Optn) C2C12 cells (n = 3 in each group). Cells were collected at 0, 2, and 4 days postdifferentiation, respectively. (I) Representative immunofluorescence staining of MYHC in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation. The empty pcDNA 3.1-HA vector or pcDNA 3.1-HA-Optn vector were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (J, K) Quantification of the distribution of nucleus per myotube and the fusion index (a MYHC+ cell with at least 3 nucleus) in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation (n = 4 in each group). (L–N) Representative immunoblotting analysis (L) and quantification (M, N) of MYHC and MYOG in control (empty vector) or Optn-OE C2C12 cells (n = 3 in each group). Cells were collected at 0, 2, and 4 days postdifferentiation, respectively. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . KD, knockdown; MYOG, myogenin; MYHC, myosin heavy chain; OE, overexpressing; OPTN, optineurin; SEM, standard error of the mean.

OPTN promotes myoblast differentiation mediated myogenesis.

(A) Representative immunoblotting analysis of OPTN and MYOG in C2C12 cells during differentiation at the indicated time points (0, 2, 4, 6, and 8 days) (n = 3 in each group). (B) Representative immunofluorescence analysis of OPTN subcellular distribution in myotubes. The OPTN and MYHC were stained with anti-OPTN antibody and anti-MYHC antibody in C2C12 cells at 4 days postdifferentiation. Scale bars: 10 um. (C) Representative immunofluorescence staining of MYHC in control (si-control) or Optn KD (si-Optn) C2C12 cells at 4 days postdifferentiation. si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (D, E) Quantification of the nucleus distribution per myotube and fusion index (a MYHC+ cell with at least 3 nucleus) in control (si-control) or Optn KD (si-Optn) C2C12 cells at 4 days postdifferentiation (n = 4 in each group). (F–H) Representative immunoblotting analysis (F) and quantification (G, H) of MYHC and MYOG in control (si-control) or Optn KD (si-Optn) C2C12 cells (n = 3 in each group). Cells were collected at 0, 2, and 4 days postdifferentiation, respectively. (I) Representative immunofluorescence staining of MYHC in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation. The empty pcDNA 3.1-HA vector or pcDNA 3.1-HA-Optn vector were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (J, K) Quantification of the distribution of nucleus per myotube and the fusion index (a MYHC+ cell with at least 3 nucleus) in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation (n = 4 in each group). (L–N) Representative immunoblotting analysis (L) and quantification (M, N) of MYHC and MYOG in control (empty vector) or Optn-OE C2C12 cells (n = 3 in each group). Cells were collected at 0, 2, and 4 days postdifferentiation, respectively. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . KD, knockdown; MYOG, myogenin; MYHC, myosin heavy chain; OE, overexpressing; OPTN, optineurin; SEM, standard error of the mean.

OPTN enhances myogenesis through activation of canonical Wnt signaling pathway

To explore the underlying mechanism of OPTN-mediated myogenesis, we analyzed the available gene expression profiles in Optn KD Hela cells (GSE6819), a common model for deep transcriptome analysis [35,36] and a fast way to gain preliminary indications. The result showed high implication of OPTN in the regulation of Wnt signaling pathway (Fig 3A), a well-characterized pathway in myogenesis [15], with down-regulation of Wnt signaling pathway target genes [MYC proto-oncogene (Myc) [37], cyclin D3 (Ccnd3) [38], twist family BHLH transcription factor 2 (Twist2) [39], and MYCN proto-oncogene (Mycn) [40]] (Fig 3B). Consistent with this, we showed reduced mRNA levels of Wnts target genes in Optn KD C2C12 cells (Fig 3C). TCF/LEF is the major transcription factor of Wnts target genes [41]. The TOP/FOP reporter assay showed markedly decreased transcription activity of TCF/LEF in Optn KD C2C12 cells, while increased in Optn-OE C2C12 cells (Fig 3D). It has been shown that enhanced transcription activity of TCF/LEF is mediated by increased nuclear translocation of β-catenin, which further forms a complex with the TCF/LEF transcription factors to regulate Wnts target genes [17]. In agreement with this, Optn OE increased the nuclear levels of β-catenin in C2C12 cells, whereas Optn KD reduced these levels (Fig 3E, S7A and S7B Fig). Similarly, Optn KD also decreased nuclear levels of active β-catenin in TA muscle at day 5 postinjury in mice (Fig 3F). Furthermore, treatment of Wnt3a, a classical ligand of the Wnt signaling pathway [20], failed to effectively increase the nuclear levels of β-catenin in Optn KD C2C12 cells (Fig 4A) and TA muscle at day 5 postinjury (Fig 4B), suggesting that OPTN is required for the activation of canonical Wnt signaling pathway. Together, these results suggest that OPTN activates canonical Wnt signaling pathway during myogenesis.
Fig 3

OPTN activates canonical Wnt signaling pathway in myoblasts.

(A) KEGG pathway enrichment analysis in si-Optn Hela cells from the GEO dataset (GSE6819). (B) Heatmap of the changes in selected Wnts target genes expression levels in si-control and si-OPTN Hela cells by RNA-seq from the GEO dataset (GSE6819). (C) Representative mRNA expression analysis of Wnt target genes in si-control or si-Optn C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (D) Representative luciferase activity of TOP/FOP in Optn-KD (left panel) and Optn-OE (right panel) C2C12 cells at 4 days postdifferentiation (n = 5 in each group). (E, F) Representative immunoblotting analysis and quantification of active β-catenin protein levels in nuclear lysates extracted from Optn-OE and Optn KD C2C12 cells at 4 days postdifferentiation (E) (n = 3 in each group) and in nuclear lysates extracted from scramble shRNA or shOptn TA muscle at 5 days postinjury (F) (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; AMPK, AMP-activated protein kinase; Birc5, baculoviral IAP repeat containing 5; Ccnd3, cyclin D3; GEO, Gene Expression Omnibus; HIF, Hypoxia-inducible factor; H3, histone H3; KD, knockdown; KEGG, Kyoto Encyclopedia of Genes and Genomes; Myc, MYC proto-oncogene; Mycn, MYCN proto-oncogene; OE, overexpression; Optn, optineurin; PPAR, peroxisome proliferator-activated receptor; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior; Tcf7l2, transcription factor 7 like 2; TCF/LEF, T-cell factor/lymphoid enhancer factor; Twist2, twist family BHLH transcription factor 2.

Fig 4

GSK3β is negatively regulated by OPTN during myogenesis.

(A, B) Representative immunoblotting analysis and quantification of active β-catenin protein levels in nuclear lysates extracted from si-control or si-Optn C2C12 cells incubated with Wnt3a or PBS for 24 hours at 4 days postdifferentiation (A) (n = 3 independent experiment) and scramble shRNA or shOptn TA muscle (intramuscular injection of Wnt3a at 1.5 days postinjury) at 5 days postinjury (B) (n = 3 mice in each group). (C–E) Representative immunoblotting analysis (upper panel) and quantification (lower panel) of DVL2 phosphorylation, GSK3β, AXIN, and APC protein levels in Optn-OE (C) and Optn KD (D) C2C12 cells at 4 days postdifferentiation (n = 3 in each group), as well as in scramble shRNA or shOptn muscle TA muscle at 5 days postinjury (E) (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; APC, adenomatous polyposis coli protein; AXIN, axis inhibition protein; BSA, bovine serum albumin; DVL2, disheveled-2; GSK3β, glycogen synthase kinase 3β; H3, histone H3, KD, knockdown; OE, overexpressing; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior.

OPTN activates canonical Wnt signaling pathway in myoblasts.

(A) KEGG pathway enrichment analysis in si-Optn Hela cells from the GEO dataset (GSE6819). (B) Heatmap of the changes in selected Wnts target genes expression levels in si-control and si-OPTN Hela cells by RNA-seq from the GEO dataset (GSE6819). (C) Representative mRNA expression analysis of Wnt target genes in si-control or si-Optn C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (D) Representative luciferase activity of TOP/FOP in Optn-KD (left panel) and Optn-OE (right panel) C2C12 cells at 4 days postdifferentiation (n = 5 in each group). (E, F) Representative immunoblotting analysis and quantification of active β-catenin protein levels in nuclear lysates extracted from Optn-OE and Optn KD C2C12 cells at 4 days postdifferentiation (E) (n = 3 in each group) and in nuclear lysates extracted from scramble shRNA or shOptn TA muscle at 5 days postinjury (F) (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; AMPK, AMP-activated protein kinase; Birc5, baculoviral IAP repeat containing 5; Ccnd3, cyclin D3; GEO, Gene Expression Omnibus; HIF, Hypoxia-inducible factor; H3, histone H3; KD, knockdown; KEGG, Kyoto Encyclopedia of Genes and Genomes; Myc, MYC proto-oncogene; Mycn, MYCN proto-oncogene; OE, overexpression; Optn, optineurin; PPAR, peroxisome proliferator-activated receptor; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior; Tcf7l2, transcription factor 7 like 2; TCF/LEF, T-cell factor/lymphoid enhancer factor; Twist2, twist family BHLH transcription factor 2.

GSK3β is negatively regulated by OPTN during myogenesis.

(A, B) Representative immunoblotting analysis and quantification of active β-catenin protein levels in nuclear lysates extracted from si-control or si-Optn C2C12 cells incubated with Wnt3a or PBS for 24 hours at 4 days postdifferentiation (A) (n = 3 independent experiment) and scramble shRNA or shOptn TA muscle (intramuscular injection of Wnt3a at 1.5 days postinjury) at 5 days postinjury (B) (n = 3 mice in each group). (C–E) Representative immunoblotting analysis (upper panel) and quantification (lower panel) of DVL2 phosphorylation, GSK3β, AXIN, and APC protein levels in Optn-OE (C) and Optn KD (D) C2C12 cells at 4 days postdifferentiation (n = 3 in each group), as well as in scramble shRNA or shOptn muscle TA muscle at 5 days postinjury (E) (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; APC, adenomatous polyposis coli protein; AXIN, axis inhibition protein; BSA, bovine serum albumin; DVL2, disheveled-2; GSK3β, glycogen synthase kinase 3β; H3, histone H3, KD, knockdown; OE, overexpressing; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior.

OPTN activates canonical Wnt signaling pathway through inhibition of GSK3β

To further investigate how OPTN promotes nuclear translocation of active β-catenin, we measured the phosphorylated and total levels of disheveled-2 (DVL2), a well-recognized positive regulator of the Wnt signaling pathway [42], and found no changes in Optn OE (Fig 4C) or KD C2C12 cells (Fig 4D), as well as in shOptn muscle at day 5 postinjury (Fig 4E) when compared with their respective controls. The axis inhibition protein (AXIN)/adenomatous polyposis coli protein (APC)/GSK3β destruction complex is the negative regulator of the Wnt/β-catenin pathway [43-45]. Optn OE in C2C12 cells significantly reduced protein levels of GSK3β without affecting the protein levels of AXIN and APC (Fig 4C). In line with this, Optn KD in C2C12 cells (si-Optn) (Fig 4D) and skeletal muscle (shOptn) at day 5 postinjury in mice (Fig 4E) increased GSK3β levels, with no changes in expression levels of AXIN and APC. Together, these results suggest that OPTN activates canonical Wnt signaling pathway through inhibition of GSK3β during myogenesis.

OPTN physically interacts with and targets GSK3β for autophagic degradation

Given that OPTN is a selective autophagy receptor [11], we deduced that OPTN might directly mediate the degradation of GSK3β. Cycloheximide (CHX) chasing assay showed approximately 7 hours half-life of GSK3β in si-control but approximately 10 hours in Optn KD cells (Fig 5A, S8A Fig). In contrast, Optn OE decreased the half-life of GSK3β from approximately 8 hours to approximately 5 hours (Fig 5A, S8A Fig). These results indicate that OPTN accelerates the degradation of GSK3β. The OPTN-mediated degradation of GSK3β could be blocked by the autophagy inhibitor 3-methyladenine (3-MA), but not by the proteasome inhibitor MG132 (Fig 5B, S8B Fig). We further demonstrated that the reduction of GSK3β shown in Optn OE was abolished in autophagy deficient ATG5 KO HEK 293T cells (S8C and S8D Fig). Meanwhile, the ratio of LC3II toI, which correlates with autophagic flux and represents a reliable index of autophagy [46], was up-regulated in Optn OE C2C12 cells, while down-regulated in Optn KD C2C12 cells (Fig 5C and 5D, S8E Fig). These results indicate that OPTN degrades GSK3β through autophagy pathway. Immunoprecipitation assay revealed protein–protein interaction between OPTN and GSK3β in C2C12 cells (Fig 5E). Immunofluorescence staining analysis showed colocalization of OPTN, GSK3β, and LC3 in C2C12 cells (S8F Fig). Optn KD reduced the interaction of LC3 and GSK3β in TA muscle at day 5 postinjury in mice as shown by immunoprecipitation (S8G Fig). Consistent with this, Optn KD decreased the colocalization of LC3 and GSK3β in C2C12 cells as shown by immunofluorescence staining (Fig 5F). Since OPTN has been shown to mediate autophagic degradation through LC3-interacting region (LIR) motif binding with LC3/GABARAP and UBANs binding with ubiquitin [47-49], we constructed the 2 mouse Optn point-mutants (F188A in LIR motif domain and E481G in UBAN domain) that are homologous with human mutants associated with its autophagic function [7,47,50] (S8H Fig). Compared with wild-type (WT) Optn, OE of either mutant in C2C12 cells failed to decrease the GSK3β levels (Fig 5G, S8I Fig), nor did it promote myoblast differentiation (Fig 5H and 5I), accompanied with reduced levels of MYOG and MYHC (Fig 5G, S8I Fig). These data indicate that OPTN degrades GSK3β via activating LC3-mediated autophagy.
Fig 5

OPTN degrades GSK3β via activating LC3-mediated autophagy.

(A) Representative immunoblotting analysis of GSK3β in Optn KD (up panel) and Optn OE (down panel) C2C12 cells at 4 days postdifferentiation and then treated with 50 μg/ml CHX at indicated time points (n = 3 in each group). (B) Representative immunoblotting analysis of GSK3β in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation and then treated with DMSO, the proteasome inhibitor MG132 (25 μM) or the autophagy inhibitor 3-MA (5 mM) for 6 hours (n = 3 in each group). (C, D) Representative immunoblotting analysis of LC3 in Optn OE (C) and Optn KD (D) C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (E) Immunoprecipitation of OPTN and endogenous GSK3β in Optn OE C2C12 cells. The immunoprecipitation analysis was performed in HA-Optn OE C2C12 cells incubated with anti-HA antibody or nonspecific Rabbit IgG (control) to pulldown endogenous GSK3β. (F) Representative immunofluorescence analysis of GFP-LC3 and FLAG-GSK3β in si-control and si-Optn C2C12 cells at 4 days postdifferentiation. Scale bars: 5 μm. (G) Representative immunoblotting analysis of OPTN, GSK3β, MYOG, and MYHC in empty vector, WT-Optn, Optn-F188A, and Optn-E481G OE C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (H, I) Representative immunofluorescence staining of MYHC (H) and quantification of the fusion index (I) in vector, WT-Optn, Optn-F188A, and Optn-E481G OE C2C12 cells at 4 days postdifferentiation (n = 3 in each group). The plasmid for empty pcDNA 3.1-HA vector, pcDNA 3.1-HA-Optn, pcDNA 3.1-HA-Optn-F188A, and pcDNA 3.1-HA-Optn-E481G were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . CHX, cycloheximide; GSK3β, glycogen synthase kinase 3β; KD, knockdown; Optn, optineurin; OE, overexpressing; MYHC, myosin heavy chain; MYOG, myogenin; SEM, standard error of the mean; 3-MA, 3-methyladenine.

OPTN degrades GSK3β via activating LC3-mediated autophagy.

(A) Representative immunoblotting analysis of GSK3β in Optn KD (up panel) and Optn OE (down panel) C2C12 cells at 4 days postdifferentiation and then treated with 50 μg/ml CHX at indicated time points (n = 3 in each group). (B) Representative immunoblotting analysis of GSK3β in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation and then treated with DMSO, the proteasome inhibitor MG132 (25 μM) or the autophagy inhibitor 3-MA (5 mM) for 6 hours (n = 3 in each group). (C, D) Representative immunoblotting analysis of LC3 in Optn OE (C) and Optn KD (D) C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (E) Immunoprecipitation of OPTN and endogenous GSK3β in Optn OE C2C12 cells. The immunoprecipitation analysis was performed in HA-Optn OE C2C12 cells incubated with anti-HA antibody or nonspecific Rabbit IgG (control) to pulldown endogenous GSK3β. (F) Representative immunofluorescence analysis of GFP-LC3 and FLAG-GSK3β in si-control and si-Optn C2C12 cells at 4 days postdifferentiation. Scale bars: 5 μm. (G) Representative immunoblotting analysis of OPTN, GSK3β, MYOG, and MYHC in empty vector, WT-Optn, Optn-F188A, and Optn-E481G OE C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (H, I) Representative immunofluorescence staining of MYHC (H) and quantification of the fusion index (I) in vector, WT-Optn, Optn-F188A, and Optn-E481G OE C2C12 cells at 4 days postdifferentiation (n = 3 in each group). The plasmid for empty pcDNA 3.1-HA vector, pcDNA 3.1-HA-Optn, pcDNA 3.1-HA-Optn-F188A, and pcDNA 3.1-HA-Optn-E481G were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . CHX, cycloheximide; GSK3β, glycogen synthase kinase 3β; KD, knockdown; Optn, optineurin; OE, overexpressing; MYHC, myosin heavy chain; MYOG, myogenin; SEM, standard error of the mean; 3-MA, 3-methyladenine.

Inhibition of GSK3β rescues impaired myogenesis in Optn KD cells and skeletal muscle

To determine whether GSK3β is required for OPTN-mediated myogenesis, we inhibited the activity of GSK3β by its specific inhibitor CHIR and found rescued cell fusion and multinuclear myotube formation events in Optn KD cells (Fig 6A). The numbers of MyoG+ cells were restored in Optn KD C2C12 cells treated with CHIR (Fig 6B). Consistent with the morphological improvement, CHIR treatment recovered the down-regulated expression levels of MYHC and MYOG in Optn KD differentiating myoblasts (Fig 6C and 6D) and rescued the reduced nuclear levels of β-catenin in Optn KD C2C12 cells (Fig 6E and 6F). When CHIR was injected into the TA muscle treated with AAV-shOptn after CTX injury, the small size of eMYHC+ regenerating fibers at day 5 postinjury was efficiently rescued (Fig 7A and 7B), with concurrent restoration of eMYHC, MYOG and nuclear β-catenin levels (Fig 7C–7F). Cumulatively, these data suggest that OPTN activates canonical Wnt signaling mediated myogenesis during muscle regeneration through degradation of GSK3β.
Fig 6

Inhibition of GSK3β rescues impaired myogenesis during myoblast differentiation induced by Optn KD.

(A) Representative immunofluorescence staining of MYHC (left panel) and quantification of fusion index (a MYHC+ cell with at least 3 nucleus) (right panel) in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR (20 μM) or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 20 μm. (B) Representative immunofluorescence staining of MYOG (left panel) and the percentage of MYOG+ cells (right panel) in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (C, D) Representative immunoblotting analysis (C) and quantification (D) of MYOG and MYHC in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. (E, F) Representative immunoblotting analysis (E) and quantification (F) of active β-catenin protein levels in nuclear lysates extracted from si-control and si-Optn C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . GSK3β, glycogen synthase kinase 3β; H3, histone H3; KD, knockdown; Optn, optineurin; MYHC, myosin heavy chain; MYOG, myogenin; SEM, standard error of the mean.

Fig 7

Inhibition of GSK3β rescues impaired skeletal muscle regeneration induced by Optn KD.

(A) Representative HE staining and immunofluorescence analysis of eMYHC+ fibers in scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 5 mice in each group). Scale bar = 50 μm. (B) Average CSA of regenerating eMYHC+ myofibers at 5 days postinjury (n = 5 mice in each group). (C, D) Representative immunoblotting analysis (C) and quantification (D) of myogenic markers (eMYHC and MYOG) in scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 3 mice in each group). (E, F) Representative immunoblotting analysis (E) and quantification (F) of active β-catenin protein levels in nuclear lysates extracted from scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; BSA, bovine serum albumin; CSA, cross-sectional fiber area; eMYHC, embryonic myosin heavy chain; GSK3β, glycogen synthase kinase 3β; HE, hematoxylin–eosin; H3, histone H3; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; WGA, wheat germ agglutinin; TA, tibialis anterior.

Inhibition of GSK3β rescues impaired myogenesis during myoblast differentiation induced by Optn KD.

(A) Representative immunofluorescence staining of MYHC (left panel) and quantification of fusion index (a MYHC+ cell with at least 3 nucleus) (right panel) in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR (20 μM) or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 20 μm. (B) Representative immunofluorescence staining of MYOG (left panel) and the percentage of MYOG+ cells (right panel) in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Scale bars: 50 μm. (C, D) Representative immunoblotting analysis (C) and quantification (D) of MYOG and MYHC in control (si-control) and Optn KD (si-Optn) C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. (E, F) Representative immunoblotting analysis (E) and quantification (F) of active β-catenin protein levels in nuclear lysates extracted from si-control and si-Optn C2C12 cells treated with CHIR or DMSO at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . GSK3β, glycogen synthase kinase 3β; H3, histone H3; KD, knockdown; Optn, optineurin; MYHC, myosin heavy chain; MYOG, myogenin; SEM, standard error of the mean.

Inhibition of GSK3β rescues impaired skeletal muscle regeneration induced by Optn KD.

(A) Representative HE staining and immunofluorescence analysis of eMYHC+ fibers in scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 5 mice in each group). Scale bar = 50 μm. (B) Average CSA of regenerating eMYHC+ myofibers at 5 days postinjury (n = 5 mice in each group). (C, D) Representative immunoblotting analysis (C) and quantification (D) of myogenic markers (eMYHC and MYOG) in scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 3 mice in each group). (E, F) Representative immunoblotting analysis (E) and quantification (F) of active β-catenin protein levels in nuclear lysates extracted from scramble shRNA or shOptn TA muscle (intramuscular injection of CHIR or BSA at 2.5 days postinjury) at 5 days postinjury (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; BSA, bovine serum albumin; CSA, cross-sectional fiber area; eMYHC, embryonic myosin heavy chain; GSK3β, glycogen synthase kinase 3β; HE, hematoxylin–eosin; H3, histone H3; Optn, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; WGA, wheat germ agglutinin; TA, tibialis anterior.

Discussion

The regeneration ability of skeletal muscle has a high clinical relevance in some conditions such as postinjury recovery and muscular disease, and myogenic differentiation–mediated myogenesis is a pivotal step of muscle regeneration [2,51]. Here, we identified a selective autophagy receptor OPTN from 5 independent microarray datasets as a potential regulator of myogenesis. By performing a series of in vivo and in vitro experiments, we for the first time showed that OPTN activates Wnt signaling pathway mediated myogenesis through autophagic degradation of GSK3β during muscle regeneration. Our findings extend the understanding of regulatory mechanisms upon Wnt signaling pathway during muscle regeneration and reveal OPTN as a potential therapeutic target for defective muscle regeneration. OPTN promotes myogenesis via activating canonical Wnt signaling pathway. The pathway is critical for myogenesis during muscle regeneration [52], regulating SCs differentiation through β-catenin binding with transcription factor 4 (TCF4) on the promoter of MYOG [53,54]. The stabilization of β-catenin is regulated by its destruction complex components. GSK3β, an important component of β-catenin destruction complex [45], is inhibited by Wnts to stabilize β-catenin and activate its nuclear translocation. There are several interpretations on Wnt-mediated inhibition of GSK3β in different models, including dissociation of GSK3β from AXIN via conformational changes [55] or posttranslational modifications [56], recruitment of GSK3 inhibitory proteins such as frequently rearranged in advanced T-cell lymphomas (FRATs) [57], or degradation of AXIN [58]. In addition, Wnts were reported to inhibit GSK3β activity by promoting its sequestration from the cytosol into multivesicular endosomes/bodies fusing with lysosome in 293T cells [59,60]. These findings shed fresh light on the inhibition of GSK3β and arouse broad interest in the field [61]. Based on the fact that the multivesicular endosome/body is an obligatory step before degradation in autophagosome [62,63], degradation might be the final fate of Wnt-induced GSK3β sequestration. Consistent with this, our data show GSK3β degradation mediated by OPTN in autophagosome during myogenesis, corroborating that OPTN involves in Wnt-mediated inhibition of GSK3β. These findings expand insights into the canonical Wnt/GSK3β/β-catenin signaling and reveal a novel mechanism on GSK3β inhibition in skeletal muscle. OPTN is an autophagy receptor that plays a central role in selective autophagy [9]. Our data demonstrate that OPTN activates Wnt signaling pathway through autophagic degradation of GSK3β in muscle, suggesting an interaction between autophagy and Wnt signaling pathway during myogenesis. In fact, conflicting results on their relationship have been reported. Up-regulation of autophagy is observed during the formation of mature myotubes and muscle regeneration [64-66], whereas inhibition of DVL2 autophagic degradation (a positive regulator of Wnt signaling pathway) is paradoxically capable of promoting Wnt signaling during muscle regeneration [67]. Similar results have been confirmed by Gao and colleagues, showing that autophagy inhibits Wnt signaling pathway by promoting Dvl2 degradation [68]. These results suggest negative regulation of Wnt signaling pathway by autophagy. Nevertheless, it has recently been reported that autophagy directly promotes nuclear translocation of β-catenin in a GSK3β dependent manner in C2C12 cells [69]. Consistently, our findings suggested that autophagy mediated OPTN-GSK3β axis exerts positive effects on Wnt signaling pathway during myogenic differentiation upon injury. In line with this, during hepatic progenitor cell differentiation, autophagy activates Wnt signaling pathway through interaction of p62 and phosphorylated GSK3β [70]. During adipocyte differentiation, a positive regulator of autophagy tumor protein P53 inducible nuclear protein 2 (TP53INP2) activates Wnt signaling pathway through autophagy-dependent sequestration of GSK3β [61]. Together, these findings suggest that the indeterminate intercommunication between autophagy and Wnt signaling pathway might be affected by dissimilar (negative or positive) regulators. In summary, our data identify a novel function of OPTN for myogenesis during muscle regeneration. OPTN promotes myogenesis during muscle regeneration through autophagic degradation of Wnt signaling pathway inhibitor GSK3β (Fig 8). These findings uncover an OPTN/GSK3β/β-catenin axis that regulates myogenesis during muscle regeneration. Thus, OPTN may be a potential therapeutic target for the prevention and treatment of impaired myogenesis in injury and other muscular disease, such as DMD [71] and aging [72]. Further investigation is needed to assess the myogenic function of OPTN in advanced models to increase its impact on translational medicine.
Fig 8

Schematic model of the role of OPTN on myogenesis during muscle regeneration.

OPTN physically interacts with and targets GSK3β for autophagic degradation and then promotes the nuclear translocation of β-catenin, resulting in activation of Wnt signaling pathway mediated myogenesis during muscle regeneration. APC, adenomatous polyposis coli protein; AXIN, axis inhibition protein; GSK3β, glycogen synthase kinase 3β; LEF/TCF, lymphoid enhancer factor/T-cell factor; LRP, low-density lipoprotein receptor related protein, OPTN, optineurin.

Schematic model of the role of OPTN on myogenesis during muscle regeneration.

OPTN physically interacts with and targets GSK3β for autophagic degradation and then promotes the nuclear translocation of β-catenin, resulting in activation of Wnt signaling pathway mediated myogenesis during muscle regeneration. APC, adenomatous polyposis coli protein; AXIN, axis inhibition protein; GSK3β, glycogen synthase kinase 3β; LEF/TCF, lymphoid enhancer factor/T-cell factor; LRP, low-density lipoprotein receptor related protein, OPTN, optineurin.

Materials and methods

Animal studies

Six-week-old male C57BL/6J mice purchased from the animal center of Xi’An Jiao Tong University (Xi’an, Shaanxi, PRC) were performed in accordance with the National Institutes of Health (Bethesda, Maryland, United States of America) Guide for the Care and Use of Laboratory Animals and with the approval of Animal Ethical and Welfare Committee of Northwest A&F University (Yang Ling, Shaanxi, PRC) [Approval ID: NWAFU-314031143]. All mice were housed with a 12-hour dark/light cycle with food and water ad libitum and were randomly allocated to the indicated groups. AAV serotype 9 vectors encoding a control scrambled shRNA sequence (scrambled; 5′-TTCTCCGAACGTGTCACGTAA-3′) or a short hairpin targeting OPTN (shOptn; 5′-GCAAATGGCCATTCTTCTA-3′) under the control of a U6 promoter and expressing EGFP (driven by a CMV promoter) were obtained from Hanbio (Shanghai, PRC). A single dose of 1.1 × 1012 vg/mice in 40 μL of AAV2/9 expressing shOptn was delivered to 8-week-old mice injected locally into the right TA muscle, and the same dose of AAV2/9 expressing shRNA control was injected left TA muscle as AAV-shRNA control group. Production and purification of recombinant AAV were made by Hanbio. Mice were treated after recombinant AAV injection for 4 weeks. To induce muscle injury, 50 μl of 10 μM CTX (HF005, Heng Fei Biotechnology, Shanghai, PRC) was injected into TA muscle. The TA muscle was harvested at 0, 3, 5, and 14 days postinjury. To verify the activity of canonical Wnt signaling in vivo, the TA muscle of scrambled shRNA or shOptn was injected with 20 μl Wnt3a (100 ng/ml, 315–20, PeproTech, New Jersey, USA) or PBS (0.1% BSA) per mouse at 1.5 days postinjury [67]. The injured TA muscle was then collected for western blot analysis at 5 days postinjury. To inhibit the activity of GSK3β in vivo, the TA muscle of scrambled shRNA or shOptn was injected with 20 μl CHIR-99021 (50 ng/ml, HY-13259, MedChemExpress, Shanghai, PRC) or PBS (0.1% BSA) per mouse at 2.5 days postinjury [67]. The injured TA muscle was then collected for hematoxylin–eosin (HE) analysis and western blotting at 5 days postinjury.

Histological analysis

The TA muscle was fixed with 4% paraformaldehyde for more than 72 hours and then subjected to dehydration embedding. Finally, paraffin sections of muscle were obtained at a thickness of 2 to 4 μm for HE staining, and whole-slide digital images were collected with an Pannoramic DESK Scanner (P-MIDI, P250, 3D HISTECH, Hungary).

5-Ethynyl-2′-deoxyuridine assays in vivo and in vitro

Mice were given intraperitoneal injection of 5-Ethynyl-2′-deoxyuridine (EdU) (50 mg/kg body weight, intraperitoneal injection; HY-118411, MedChemExpress) 2 consecutive days before analyzed. EdU was detected with the Cell-Light Apollo 567 Stain Kit (C10317-1, RiboBio, Guangzhou, PRC). About 200 nucleus per sample from one mouse were counted. EdU and Pax7 double-positive nucleus, EdU-positive nucleus, and total cell nucleus were counted using ImageJ. The proliferation of C2C12 myoblasts cultured was determined using the Cell-Light EdU Apollo 567 In Vitro Kit (C10310-1, RiboBio) according to manufacturer’s instructions. EdU-positive nucleus and total cell nucleus were counted using ImageJ.

Cell culture

C2C12 cells were purchased from China Infrastructure of Cell Line Resource and were cultured in growth medium comprising high-glucose Dulbecco’s Modified Eagle medium (DMEM) (H30022.01, HyClone, Connecticut, USA) supplemented with 10% fetal bovine serum (FBS) (Z7186FBS-500, ZETA LIFE, California, USA), 1% penicillin/streptomycin. After 48 hours, C2C12 cells were cultured in differentiation medium (high-glucose DMEM supplemented with 2% horse serum and 1% penicillin/streptomycin). Atg5+/+ and Atg5−/− HEK293T cell lines were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Atg5+/+ and Atg5−/− HEK293T cell lines were kindly provided by Dr. Jun Cui (School of Life Sciences, Sun Yat-sen university).

Plasmids and RNA interference

In order to construct a plasmid encoding HA-OPTN, HA-OPTN-F188A, and OPTN-E481G, the HA-tag was added at the N-terminus of OPTN, OPTN-F188A, and OPTN-E481G. The WT-OPTN, OPTN-F188A, and OPTN-E481G were cloned into the BamHI and XhoI sites of the pcDNA3.1-HA vector. In order to construct a plasmid encoding FLAG-GSK3β, the FLAG tag was added at the N-terminus of GSK3β. GSK3β was then cloned into the NotI and XbaI sites of the pcDNA3.1-FLAG vector. The pcDNA3.1-HA, pcDNA3.1-FLAG, and GFP-LC3B plasmid were provided by Dr. Qingzhu Sun (College of Animal Science and Technology, Northwest A&F University). The TOP flash/FOP flash and Renilla luciferase expression plasmids was provided by Dr. Qingyong Meng (College of Biological Sciences, China Agricultural University). The si-control, si-Optn, and si-β-catenin were synthesized from GenePharma (Shanghai, PRC). The sequences of Optn and β-catenin siRNAs were as follows: Optn siRNA1, 5′-GCAGACUUACCUGUUUCAATT-3′; Optn siRNA2, 5′-GCAAAUGGCCAUUCUUCUATT-3′.

Plasmid transfection and luciferase reporter assay

The plasmids were transfected into C2C12 cells and HEK293T cells using Lipofectamine 3000 (L3000001, Invitrogen, California, USA). In order to identify the activity of canonical Wnt signaling, the TOP flash/FOP flash expression plasmids with the Renilla luciferase expression plasmid were transfected when si-control and si-Optn C2C12 cells or HA-vector and HA-Optn were cultured after 2 days in the differentiation medium. The reporter activity was measured using the Dual-luciferase Reporter Assay System (E1980, Promega, Wisconsin, USA).

Immunofluorescence

Muscle sections and cultured cells were fixed in 4% formaldehyde for 10 minutes, permeabilized with 0.2% Triton X-100 for 20 minutes on ice, and then blocked in 3% bovine serum albumin in PBS for 1 hour. The samples were blocked in 5% BSA for 2 hours at room temperature. Primary antibodies listed in S1 Table were incubated in blocking buffer at 4°C overnight. Subsequently, the samples were washed with PBS and stained with the appropriate fluorescently labeled secondary antibodies (fluorescein isothiocyanate or rhodamine) for 1 hour at room temperature. After washing with PBS, DAPI (C0060, Solarbio, Beijing, PRC) was used to stain nucleus for 3 minutes. For immunostaining of muscle sections, whole-slide digital images were collected with an Pannoramic DESK Scanner (P-MIDI, P250, 3D HISTECH). Cross-sectional area of the new myofibers was calculated on section images obtained from TA muscle using ImageJ. For immunostaining of cultured cells, images were acquired using BioTEK gen 5 Software. Total cell nucleus and nucleus within myotubes were counted using ImageJ. The distribution of nucleuses per myotube and fusion index (a MYHC+ cell with at least 3 nucleuses) was calculated as the number of nucleuses in myotubes divided by the total number of nucleuses counted.

Real-time reverse transcriptase PCR

Real-time PCR were performed as described [73]. Total RNA was isolated from the fresh TA muscle using TRIzol reagent (9109, Takara, Shiga, Japan). Complementary DNA (cDNA) was synthesized from total RNA using cDNA synthesis kit (R333-01, Vazyme Biotech, Nanjing, China) following the manufacturer’s instructions. RT-PCR was performed using a CFX 96 Real-Time PCR Detection System (Bio-Rad, Hercules, California, USA). Each 20 mL amplifications contained 10 μl of ChamQ SYBR qPCR Master Mix (Q222-01, Vazyme Biotech), 7.8 mL of sterilized double-distilled water, 1 mL of 1:10 diluted cDNA, and 0.6 mL of each forward and reverse primer. The RT-qPCR program comprised an initial activation step at 95°C for 3 minutes, followed by 38 cycles of 95°C for 15 seconds and 60°C for 30 seconds, and 5 seconds at 65°C. After the PCR, a single product generated in these reactions was confirmed via melting curve analyses. The comparative Ct method (2−ΔΔCt), described in the literature [74] was used to calculate the gene expression values. The primer sequences for genes were listed in S2 Table.

Immunoblotting

C2C12 cells and TA muscle were washed with PBS and lysed in RIPA lysis buffer (P0013C, Beyotime Biotechnology, Shanghai, PRC). Next, 200 μg of total protein was resolved by 10% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis and transferred onto a polyvinylidene fluoride (PVDF) (IPVH00010, Millipore, Massachusetts, USA) membrane via electroblotting. The PVDF membrane was blocked in black buffer (5% skim milk powder dissolved in TBST) for 2 hours at room temperature. Primary antibodies listed in S1 Table were applied in TBST at 4°C overnight. Subsequently, the PVDF membrane was washed 4 times with TBST (5 minutes per time) and stained with the secondary antibodies (goat anti-rabbit or mouse) for 2 hours at room temperature. After washing with TBST, the ECL Reagent (WBKlS0100, Millipore) was used, and the strips were on film.

Immunoprecipitation

For immunoprecipitation analysis, the TA muscle and cultured cells were homogenized with IP lysis buffer (containing 1M pH 7.4 Tris-HCl 25ml, NP40 25ml, NaCl 4.383g, EDTA 0.146g, glycerin 50 ml, and protease inhibitor cocktail), and the total protein was incubated with 5 μg of the Rabbit monoclonal antibody to HA, GSK3β, or nonspecific Rabbit IgG for 2 hours at room temperature and then immunoprecipitation with protein A/G magnetic beads (B23201, Bimaker, Shanghai, PRC) at 4°C overnight. After washing 3 times with TPBS (5 minutes per time), the protein-bound beads were finally resuspended in 20 μl 1× SDS-PAGE loading buffer. The samples were boiled at 95°C for 10 minutes, and the supernatant was loaded on the gel for immunoblotting.

Treatment with reagents in cell culture

In order to verify the activity of canonical Wnt signaling, si-control and si-OPTN C2C12 cells were treated with either Wnt3a (100 ng/ml, 315–20, PeproTech) or PBS for 24 hours after 2 days in differentiation medium. The cell samples were then collected for western blot analysis. In order to inhibit the activity of GSK3β in OPTN KD C2C12 cells, the OPTN KD C2C12 cells were treated with CHIR-99021 (CHIR; 3 μM, HY-10182, MedChemExpress) during differentiation. Western blotting and immunofluorescence analysis were performed after 4 days of differentiation. For CHX chasing assay, cells were treated with CHX (50 μg/ml) and collected at the indicated time points and prepared for western blot analysis. To determine which degradation system dominantly controls the degradation of GSK3β, DMSO, MG132 (25 μM, HY-13259, MedChemExpress), and 3-MA (5 mM, HY-19312, MedChemExpress) were added to C2C12 cells cultured for 6 hours with or without Optn OE to detect the protein expression of GSK3β via western blotting.

Statistical analysis

All experiments were at least performed in 3 independent experiments. Data are presented as mean ± standard error of the mean and were analyzed by 2-tailed Student t tests for comparisons between 2 groups or 2-way analysis of variance (ANOVA) with Duncan post hoc test for multiple comparisons. Statistical significance was defined as *P < 0.05 versus controls. All data were analyzed using PASW Statistics 20 (SPSS, Chicago, Illinois, USA).

The quantification of OPTN and eMYHC immunoblotting analysis during muscle regeneration.

(A) The quantification of OPTN immunoblotting analysis in TA of WT mice at 0, 3, 5, and 14 days postinjury (n = 3 mice in each group). (B) The quantification of eMYHC immunoblotting analysis in TA of WT mice at 0, 3, 5, and 14 days postinjury (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in S1 Data. CTX, cardiotoxin; eMYHC, embryonic myosin heavy chain; OPTN, optineurin; SEM, standard error of the mean; TA, tibialis anterior; WT, wild-type. (TIF) Click here for additional data file.

Representative immunofluorescence analysis of OPTN and eMYHC in TA muscle at 5 days postinjury.

The OPTN, newly regenerated myofibers, and nucleus were stained with anti-OPTN antibody (red), anti-eMYHC antibody (green), and DAPI (blue), respectively. Scale bars: 50 um. eMYHC, embryonic myosin heavy chain; OPTN, optineurin; TA, tibialis anterior. (TIF) Click here for additional data file.

The efficiency of OPTN KD in mouse TA muscle by AAV shRNA.

(A) Representative immunoblotting analysis (left panel) and quantification (right panel) of the OPTN in C2C12 myoblasts with si-control or si-Optn #1–2 transfection (n = 3 in each group). (B) Representative fluorescence image at 4 weeks postinjection of AAV containing scramble RNA or shOptn. (C) Quantification of Optn mRNA expression in TA muscle at 4 weeks postinjection of AAV containing scramble RNA or shOptn (n = 5 mice in each group). Representative immunoblotting analysis (left panel) and quantification (right panel) of the OPTN in TA muscle at 4 weeks postinjection of AAV containing scramble RNA or shOptn (n = 3 mice in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; KD, knockdown; OPTN, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior. (TIF) Click here for additional data file.

OPTN does not affect cell proliferation.

(A) Representative immunofluorescence staining of Pax7 (green), EdU (red), and DAPI (blue) in scramble shRNA or shOptn TA muscle at 3 days postinjury. Scale bar: 50 μm. (B) Quantification of the percentage of Pax7+EdU+ cells in scramble shRNA or shOptn TA muscle at 3 days postinjury (n = 5 mice in each group). (C) Representative immunofluorescence staining of Pax7 (red) and DAPI (blue) in scramble shRNA or shOptn TA muscle at 3 days postinjury. Scale bar: 50 μm. (D) Quantification of the percentage of Pax7+ cells in scramble shRNA or shOptn TA muscle at 3 days postinjury (n = 5 mice in each group). (E) Representative EdU and DAPI staining analysis in control (si-control) and Optn KD (si-Optn) C2C12 cells. si-control or si-Optn were transfected into C2C12 cells for 24 hours before staining analysis. Scale bar: 300 μm. (F) Quantification of the percentage of EdU-positive cells/total cells in control (si-control) and Optn KD (si-Optn) C2C12 cells (n = 5 in each group). si-control or si-Optn were transfected into C2C12 cells for 24 hours before staining analysis. (G) Representative mRNA expression analysis of cell proliferation–associated genes in C2C12 cells with si-control or si-Optn transfection (n = 6 in each group). Cells were collected after 24h transfection. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . AAV, adeno-associated viral vector; EdU, 5-Ethynyl-2′-deoxyuridine; KD, knockdown; OPTN, optineurin; Pax7, paired box 7; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior. (TIF) Click here for additional data file.

The quantification of OPTN and MYOG immunoblotting analysis in C2C12 cells during differentiation.

(A) The quantification of OPTN immunoblotting analysis in C2C12 cells during differentiation at the indicated time points (0, 2, 4, 6, and 8 days) (n = 3 in each group). (B) The quantification of MYOG immunoblotting analysis in C2C12 cells during differentiation at the indicated time points (0, 2, 4, 6, and 8 days) (n = 3 in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . MYOG, myogenin; Optn, optineurin; SEM, standard error of the mean. (TIF) Click here for additional data file. (A, B) Representative immunoblotting analysis (A) and quantification (B) of OPTN, MYHC, and MYOG in si-control or si-Optn C2C12 cells at 4 days postdifferentiation (n = 3 in each group). si-control or si-Optn were transfected into C2C12 cells for 48 hours before the initiation of differentiation. (C, D) Representative immunoblotting analysis (C) and quantification (D) of OPTN, MYHC and MYOG in control (empty vector) and Optn OE C2C12 cells at 4 days postdifferentiation (n = 3 in each group). The empty pcDNA 3.1-HA vector or pcDNA 3.1-HA-Optn vector were transfected into C2C12 cells for 48 hours before the initiation of differentiation. Cells were collected at 4 days postdifferentiation. Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . MYOG, myogenin; MYHC, myosin heavy chain; OE, overexpressing; Optn, optineurin; SEM, standard error of the mean. (TIF) Click here for additional data file.

OPTN enhances nuclear β-catenin levels in C2C12 cells.

(A, B) Representative immunofluorescence analysis of active β-catenin in Optn OE (A) and Optn KD (B) C2C12 cells at 4 days postdifferentiation. Scale bar: 10 μm. KD, knockdown; OE, overexpressing; Optn, optineurin. (TIF) Click here for additional data file. (A) The quantification of GSK3β immunoblotting analysis in Optn KD (left panel) and Optn OE (right panel) C2C12 cells at 4 days postdifferentiation and then treated with 50 μg/ml CHX at indicated time points (n = 3 in each group). (B) The quantification of GSK3β immunoblotting analysis in control (empty vector) or Optn-OE C2C12 cells at 4 days postdifferentiation and then treated with DMSO, the proteasome inhibitor MG132 (25 μM), or the autophagy inhibitor 3-MA (5 mM) for 6 hours (n = 3 in each group). (C, D) Representative immunoblotting analysis (C) and quantification (D) of GSK3β in WT and Atg5 KO HEK293T cells transfected with vector or Optn-OE (n = 3 in each group). (E) The quantification of LC3 immunoblotting analysis in Optn OE and Optn KD C2C12 cells at 4 days postdifferentiation (n = 3 in each group). (F) Representative immunofluorescence analysis of GFP-LC3, HA-OPTN, and FLAG-GSK3β in C2C12 cells transfected with GFP-LC3, HA-OPTN plasmids, and FLAG-GSK3β plasmids. Scale bars: 5 μm. (G) Co-immunoprecipitation analysis of LC3 and GSK3β in scramble shRNA or shOptn TA muscle at 5 days postinjury. The immunoprecipitation analysis was performed in scramble shRNA or shOptn TA muscle at 5 days postinjury incubated with anti-GSK3β antibody or nonspecific Rabbit IgG (control) to pulldown endogenous LC3. (H) Schematic illustration of the domain organization and molecular validation of mouse Optn-F188A and Optn-E481G point-mutant plasmids. (I) The quantification of OPTN, GSK3β, MYHC, and MYOG immunoblotting analysis in empty vector, WT-Optn, Optn-F188A, and Optn-E481G overexpressing C2C12 cells at 4 days postdifferentiation (n = 3 in each group). Data are presented as mean ± SEM. *P < 0.05 versus control. The underlying data for this figure can be found in . The original blot for this figure can be found in . AAV, adeno-associated viral vector; CHX, cycloheximide; GSK3β, glycogen synthase kinase 3β; KD, knockdown; KO, knockout; LIR, LC3-interacting region; MYHC, myosin heavy chain; MYOG, myogenin; OE, overexpressing; OPTN, optineurin; SEM, standard error of the mean; shRNA, short hairpin RNA; TA, tibialis anterior; UBAN, ubiquitin-binding domain; 3-MA, 3-methyladenine. (TIF) Click here for additional data file.

Primary antibodies used in this study.

(DOCX) Click here for additional data file.

qRT-PCR primers used in this study.

(DOCX) Click here for additional data file.

Contains underlying data for Figs 1A, 1F, 1G, 1I, 1J, 2D, 2E, 2G, 2H, 2J, 2K, 2M, 2N, 3A, 3B, 3C, 3D, 3F, 4A, 4B, 4C, 4D, 4E, 5I, 6A, 6B, 6D, 6F, 7B, 7D, and 7F and S1A, S1B, S3A, S3C, S3D, S4B, S4D, S4F, S4G, S5A, S5B, S6B, S6D, S8A, S8B, S8D, S8E, and S8I Figs.

(XLSX) Click here for additional data file.

Original blot contains Figs 1B, 1H, 2A, 2F, 2L, 3E, 3F, 4A, 4B, 4C, 4D, 4E, 5A, 5B, 5C, 5D, 5E, 5G, 6C, 6E, 7C, and 7E and S3A, S3D, S6A, S6C, S8C, and S8G Figs.

(PDF) Click here for additional data file.
  74 in total

1.  Wnt signaling regulates the function of MyoD and myogenin.

Authors:  A G Ridgeway; H Petropoulos; S Wilton; I S Skerjanc
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

2.  Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration.

Authors:  Anna Polesskaya; Patrick Seale; Michael A Rudnicki
Journal:  Cell       Date:  2003-06-27       Impact factor: 41.582

Review 3.  Building muscle: molecular regulation of myogenesis.

Authors:  C Florian Bentzinger; Yu Xin Wang; Michael A Rudnicki
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 4.  Muscle cell communication in development and repair.

Authors:  Alexis R Demonbreun; Elizabeth M McNally
Journal:  Curr Opin Pharmacol       Date:  2017-04-15       Impact factor: 5.547

5.  Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation.

Authors:  Chan Gao; Weipeng Cao; Lan Bao; Wei Zuo; Guoming Xie; Tiantian Cai; Wei Fu; Jian Zhang; Wei Wu; Xu Zhang; Ye-Guang Chen
Journal:  Nat Cell Biol       Date:  2010-07-18       Impact factor: 28.824

6.  WNT/β-Catenin Signaling Regulates Multiple Steps of Myogenesis by Regulating Step-Specific Targets.

Authors:  Akiko Suzuki; Richard C Pelikan; Junichi Iwata
Journal:  Mol Cell Biol       Date:  2015-03-09       Impact factor: 4.272

7.  Deep proteome and transcriptome mapping of a human cancer cell line.

Authors:  Nagarjuna Nagaraj; Jacek R Wisniewski; Tamar Geiger; Juergen Cox; Martin Kircher; Janet Kelso; Svante Pääbo; Matthias Mann
Journal:  Mol Syst Biol       Date:  2011-11-08       Impact factor: 11.429

8.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

Authors:  Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong
Journal:  Autophagy       Date:  2021-02-08       Impact factor: 13.391

9.  Increase in HDAC9 suppresses myoblast differentiation via epigenetic regulation of autophagy in hypoxia.

Authors:  Zhang Zhang; Liqiang Zhang; You Zhou; Liya Li; Jiangdong Zhao; Wen Qin; Zuolin Jin; Wenjia Liu
Journal:  Cell Death Dis       Date:  2019-07-18       Impact factor: 8.469

10.  Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts.

Authors:  Jon Sin; Allen M Andres; David J R Taylor; Thomas Weston; Yoshimi Hiraumi; Aleksandr Stotland; Brandon J Kim; Chengqun Huang; Kelly S Doran; Roberta A Gottlieb
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.